Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

1996 • 384 citations

Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)

1993 • 293 citations

Topoisomerase I inhibitors: topotecan and irenotecan

1994 • 251 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

Sentinel lymph node biopsy and axillary staging of T1–T2 N0 breast cancer: A multicenter study

1998 • 39 citations

Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)

1997 • 22 citations

A Phase II Study of 5-Fluorouracil Plus High-Dose Folinic Acid in the Treatment of Recurrent Small Cell Lung Cancer

1995 • 12 citations

In this issue

1996 • 9 citations

Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer

1993 • 8 citations